Science

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 18, 2022 - 11:30pm

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences:

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences:
    Fireside chat on May 24, 2022 starting at 8:30 a.m.
  • Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.
  • In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
  • Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for LIVMARLI for the treatment of cholestatic liver disease in patients with Alagille syndrome.

Catalyst OrthoScience Announces Todd Wilson, PhD as Vice President of Medical Education and Training

Retrieved on: 
Wednesday, May 18, 2022 - 9:12pm

Catalyst OrthoScience , a medical device company focused on the upper extremity orthopedics market, is pleased to announce that Dr. Todd Wilson has joined Catalyst as Vice President of Medical Education and Training effective immediately.

Key Points: 
  • Catalyst OrthoScience , a medical device company focused on the upper extremity orthopedics market, is pleased to announce that Dr. Todd Wilson has joined Catalyst as Vice President of Medical Education and Training effective immediately.
  • We are excited to have an executive with Todds experience join our team at Catalyst OrthoScience, said Catalyst OrthoScience CEO and President Carl OConnell.
  • My driving force is to exceed expectations by building a world-class medical education and training program with the establishment of the Catalyst Center of Excellence to serve as our foundation for growth and transformation.
  • Catalyst OrthoSciences goal is to develop innovative medical solutions that make orthopedic surgery less invasive and more efficient for both surgeons and patients.

Aptar Named Among the 100 Best Corporate Citizens for 2022

Retrieved on: 
Wednesday, May 18, 2022 - 10:00pm

3BL Media, in partnership with Institutional Shareholder Services (ISS) ESG, evaluated the 1,000 largest public U.S. companies regarding ESG and Aptar is among the top 100 companies.

Key Points: 
  • 3BL Media, in partnership with Institutional Shareholder Services (ISS) ESG, evaluated the 1,000 largest public U.S. companies regarding ESG and Aptar is among the top 100 companies.
  • View the full release here: https://www.businesswire.com/news/home/20220518006055/en/
    We are honored to be named one of the best corporate citizens for the second year in a row.
  • 3BL Media formulates its methodology based on the latest developments in corporate sustainability, extensive feedback from corporate and NGO stakeholders and guidance from Institutional Shareholder Services (ISS) ESG.
  • To view the complete 100 Best Corporate Citizens of 2022 list, please visit https://100best.3blmedia.com/ .

Agilent Announces Cash Dividend of 21 Cents per Share

Retrieved on: 
Wednesday, May 18, 2022 - 9:05pm

Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 21 cents per share of common stock will be paid on July 27, 2022, to all shareholders of record as of the close of business on July 5, 2022.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 21 cents per share of common stock will be paid on July 27, 2022, to all shareholders of record as of the close of business on July 5, 2022.
  • This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein.
  • The forward-looking statements contained herein include, but are not limited to, information regarding the companys dividend program and future payment obligations.
  • To receive the latest Agilent news, subscribe to the Agilent Newsroom .

Labcorp Launches New Test for People With Skin Cancer

Retrieved on: 
Wednesday, May 18, 2022 - 9:30pm

Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company.

Key Points: 
  • Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company.
  • The new test measures Lymphocyte-activation gene 3 (LAG-3) expression levels by immunohistochemistry (IHC) in tumor tissue.
  • The test is available for use in both clinical trials and for the care and treatment of patients.
  • According to the National Cancer Institute, skin cancer is the most common form of cancer in the United States.

Amazon Web Services Joins Q-NEXT Quantum Center

Retrieved on: 
Wednesday, May 18, 2022 - 7:19pm

Amazon Web Services (AWS) has become a member of Q-NEXT, a quantum research center that is developing the science and technology for controlling and distributing quantum information.

Key Points: 
  • Amazon Web Services (AWS) has become a member of Q-NEXT, a quantum research center that is developing the science and technology for controlling and distributing quantum information.
  • "We are excited to join Q-NEXT so we can bring together quantum experts from AWS and other top academic institutions to collaborate on the research and development of new quantum technologies and build a national quantum community," said Simone Severini, director of quantum computing at AWS.
  • The service gives researchers access to different types of quantum hardware and circuit simulators for running and testing quantum applications.
  • Now it is developing cloud quantum services, building a quantum computer, and applying quantum algorithms to real-world problems.

Tractor Supply’s Spring Paper Clover Program Raises Nearly $1.3 Million For 4-H

Retrieved on: 
Wednesday, May 18, 2022 - 4:11pm

"Our customers and Team Members have once again shown incredible generosity throughout this Paper Clover campaign.

Key Points: 
  • "Our customers and Team Members have once again shown incredible generosity throughout this Paper Clover campaign.
  • The donations, which generate scholarships for 4-H youth, were made through Paper Clover purchases at checkout through May 8, 2022.
  • To date, the Tractor Supply Paper Clover campaigns have raised more than $17 million.
  • Visit www.TractorSupply.com/4H to learn more about Tractor Supplys Paper Clover campaign, and go to www.4-H.org to learn more about 4-H programs.

Global Bispecific Antibody Market Report to 2028 - Featuring Genentech, Genmab and Merus Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 3:12pm

Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028" Report Highlights:

Key Points: 
  • Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028" Report Highlights:
    Global Bispecific Antibody Market Opportunity: > US$ 20 Billion
    Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021)
    Approved Bispecific Antibodies In Market: 4 Antibodies
    Ongoing Clinical Trials Assessment by Status, Phase, and Region
    The unique achievements gathered through the monoclonal antibody market led to the identification of a novel wave of antibody market classified as the Bispecific cancer antibody market.
  • In a very imperative and innovative way, bispecific cancer antibody market applications have prompted oncology researchers to multiply the healthcare benefits received by the patients suffering from different types of cancers.
  • The whole procedure followed by the drugs available on the market involves targeting two specific molecules present on the surface of cancer antigens.
  • Currently 3 Bispecific Antibodies Blincyto, Hemlibra & Rybrevant Are Commercially Available In Market, Hemlibra Accounts For More Than 80% Of Global Bispecific Antibody Market
    In the past few years, global bispecific cancer antibody market has cleared its clinical evaluation for different types of cancers which involves: cancer at early stage, last stage and solid cancers.

Prosperdtx Launches Strategic Collaboration With Health Equity Researchers and Seqster to Improve Health Equity for Cancer Patients

Retrieved on: 
Wednesday, May 18, 2022 - 3:14pm

Our collaboration with Seqster will enable us to demonstrate how Prosperdtxs digital health platform can help cancer patients live better lives with improved and cost-effective health outcomes.

Key Points: 
  • Our collaboration with Seqster will enable us to demonstrate how Prosperdtxs digital health platform can help cancer patients live better lives with improved and cost-effective health outcomes.
  • Seqsters Operating System will enable Prosperdtx to deliver precision cancer care to cancer patients in real-time, said Joseph Swiader, co-founder and CEO of Prosperdtx.
  • Prosperdtx is maximizing the continuity of cancer care so that patients can live longer, better lives while reducing the cost of healthcare.
  • Seqster has nationwide coverage of EHRs from hospitals and medical groups, genomic DNA, wearables, pharmacy, and social determinants of health data.

Hasbro Named to 100 Best Corporate Citizens List for 11th Consecutive Year

Retrieved on: 
Wednesday, May 18, 2022 - 4:00pm

Hasbro, Inc. (NASDAQ: HAS), a global play and entertainment company, has been named to 3BL Medias 100 Best Corporate Citizens 2022 ranking, marking the companys 11th straight year on the list.

Key Points: 
  • Hasbro, Inc. (NASDAQ: HAS), a global play and entertainment company, has been named to 3BL Medias 100 Best Corporate Citizens 2022 ranking, marking the companys 11th straight year on the list.
  • 100 Best Corporate Citizens recognizes outstanding environmental, social and governance (ESG) performance and transparency among the 1,000 largest, publicly-traded U.S. companies.
  • The 100 Best Corporate Citizens ranking is determined using a methodology developed by 3BL Media.
  • The 100 Best Corporate Citizens debuted in 1999 in Business Ethics Magazine and appeared annually in Corporate Responsibility Magazine for many years.